OS Therapies (NYSEAMERICAN:OSTX) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $20.00 price target on the stock.

OS Therapies Price Performance

OS Therapies stock opened at $1.25 on Wednesday. OS Therapies has a 12-month low of $1.12 and a 12-month high of $2.57. The stock has a market capitalization of $49.41 million, a P/E ratio of -1.26 and a beta of -2.98. The firm’s 50-day moving average is $1.38 and its two-hundred day moving average is $1.62.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share (EPS) for the quarter. As a group, analysts forecast that OS Therapies will post -0.64 EPS for the current year.

Institutional Investors Weigh In On OS Therapies

Several hedge funds have recently modified their holdings of the company. CM Management LLC boosted its stake in shares of OS Therapies by 6.7% during the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after purchasing an additional 25,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after acquiring an additional 58,350 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of OS Therapies in the third quarter worth approximately $183,000. Two Sigma Investments LP acquired a new stake in shares of OS Therapies in the third quarter worth approximately $169,000. Finally, Virtu Financial LLC boosted its position in shares of OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after acquiring an additional 54,269 shares during the last quarter.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.